Antithrombotic prophylaxis of no benefit in symptomatic outpatients with COVID-19: Lancet

Delhi: Results from two randomized trials indicate that routine use of antithrombotic therapies to prevent thromboembolic complications is futile among symptomatic outpatients with COVID-19. The...

Related Keywords

Zurich ,Züsz ,Switzerland ,Delhi ,India ,Belgium ,Brasschaat ,Region Flamande ,Stefano Barco ,Department Of Cardiology ,University Hospital Zurich ,Department Of Angiology ,Frank Cools ,General Hospital Klina ,Monitoring Board ,Data Safety ,Between Aug ,Lancet Haematology ,Outpatients ,Antithrombotic ,Prophylaxis ,Covid 19 ,Low Molecular Weight Heparin ,Enoxaparin ,Thromboprophylaxis ,Respiratory Infection ,Critically Ill Patients ,Thic Trial ,Covid Trial ,Coronavirus ,